DK1511496T3 - Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri - Google Patents

Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri

Info

Publication number
DK1511496T3
DK1511496T3 DK03741634T DK03741634T DK1511496T3 DK 1511496 T3 DK1511496 T3 DK 1511496T3 DK 03741634 T DK03741634 T DK 03741634T DK 03741634 T DK03741634 T DK 03741634T DK 1511496 T3 DK1511496 T3 DK 1511496T3
Authority
DK
Denmark
Prior art keywords
treating
aforementioned
immune mediated
pharmaceutical compositions
estrogenic component
Prior art date
Application number
DK03741634T
Other languages
Danish (da)
English (en)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Ti Coelingh
Christian Franz Holinka
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of DK1511496T3 publication Critical patent/DK1511496T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03741634T 2002-06-11 2003-06-11 Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri DK1511496T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077272 2002-06-11
PCT/NL2003/000422 WO2003103684A1 (en) 2002-06-11 2003-06-11 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein

Publications (1)

Publication Number Publication Date
DK1511496T3 true DK1511496T3 (da) 2007-02-05

Family

ID=29724474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03741634T DK1511496T3 (da) 2002-06-11 2003-06-11 Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri

Country Status (13)

Country Link
US (1) US7923440B2 (pt)
EP (1) EP1511496B1 (pt)
CN (1) CN1691947B (pt)
AT (1) ATE340579T1 (pt)
AU (1) AU2003274946A1 (pt)
CA (1) CA2489271C (pt)
CY (1) CY1105883T1 (pt)
DE (1) DE60308679T2 (pt)
DK (1) DK1511496T3 (pt)
ES (1) ES2274252T3 (pt)
PT (1) PT1511496E (pt)
SI (1) SI1511496T1 (pt)
WO (1) WO2003103684A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
WO2012164095A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
WO2015040051A1 (en) 2013-09-18 2015-03-26 Crystal Pharma, S.A.U. Process for the preparation of estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
PE20231714A1 (es) 2015-06-18 2023-10-23 Estetra Sprl Unidad de dosificacion orodispersable que contiene un componente estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
KR101996390B1 (ko) * 2017-04-21 2019-07-04 이화여자대학교 산학협력단 아미노퀴놀린계 화합물을 포함하는 면역 증강용 조성물, 조절 t 세포로의 분화 촉진용 조성물, 및 이를 이용한 방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AU8727798A (en) 1997-06-20 1999-01-04 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
AU4543200A (en) 1999-04-16 2000-11-02 Dittgen, Michael Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
US7273932B1 (en) 1999-05-28 2007-09-25 The University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
AU5984701A (en) 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy

Also Published As

Publication number Publication date
AU2003274946A1 (en) 2003-12-22
WO2003103684A1 (en) 2003-12-18
EP1511496A1 (en) 2005-03-09
ES2274252T3 (es) 2007-05-16
CN1691947A (zh) 2005-11-02
DE60308679T2 (de) 2007-08-16
ATE340579T1 (de) 2006-10-15
CA2489271C (en) 2011-12-06
SI1511496T1 (sl) 2007-04-30
EP1511496B1 (en) 2006-09-27
US7923440B2 (en) 2011-04-12
PT1511496E (pt) 2007-01-31
CA2489271A1 (en) 2003-12-18
CN1691947B (zh) 2011-11-23
DE60308679D1 (de) 2006-11-09
CY1105883T1 (el) 2011-02-02
US20050261209A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
CY1105883T1 (el) Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτη
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
DK1390040T3 (da) Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
GB0226724D0 (en) Therapeutic agents
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2002360592A8 (en) Inhibitors of hepatitis c virus
HUP0301422A2 (hu) Ösztrogén hatású szereket tartalmazó gyógyászati készítmények
SG166791A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
NO20081772L (no) Ikke-basiske antagonister av melaninkonsentrerende hormon-reseptor-1
ECSP045073A (es) Nuevos derivados de piperazina
DK1501499T3 (da) Transepikutan indgivelsesform til behandling af restless legs-syndromet
ATE533492T1 (de) Behandlung oder prävention von hypertensiven erkrankungen in der schwangerschaft oder von wachstumsverzögerung des foeten
DK1583538T3 (da) Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
DE602004009664D1 (de) Diclazurilhaltige antiprotozoenmittel
DE60041137D1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
CA2322327A1 (en) Treatment of viral disease in swine
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
DK1337246T3 (da) Anvendelse af 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens
HUP0303610A2 (hu) Jóindulatú prosztatatúltengéssel összefüggő húgyhólyag-irritációs tünetek kezelésére alkalmas készítmény